Reference Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type
PMID
Authors RB. Cohen, JP Delord, T Doi, SA Piha-Paul, SV. Liu, J Gilbert, AP Algazi, S Cresta, RL Hong, C Le Tourneau, D Day, A Varga, E Elez, JM. Wallmark, S Saraf, A Morosky, JD. Cheng, B Keam
Title Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.
Journal Vol Issue Date Pages Journal Short Title
Journal of Clinical Oncology May 20, 2016
URL http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.6017
Abstract Text Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 6017-6017 DOI: 10.1200/JCO.2016.34.15_suppl.6017

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive salivary gland carcinoma predicted - sensitive Pembrolizumab Phase I Actionable In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 12% (3/26) and a stable disease rate of 46% (12/26) in heavily pretreated patients with salivary gland carcinoma that had CD274 (PD-L1) expression in 1% or more of tumor or stroma cells by IHC, with a median duration of response of 4 months (PMID: 29462123; NCT02054806). detail... 29462123